ACTIVE

PharmaLex Belgium

Export PDF

Financial year 2024 · Closed on 30/09/2024

Net result-102,3 k €-117,7 %over 1 year

Revenue8,4 M €+19,7 %over 1 year

Equity2,4 M €-4,2 %over 1 year

Workforce47,1 ETP-5,8 %over 1 year

Identity

Source · BCE/KBO

PharmaLex Belgium is a Public limited company incorporated in 2016. Its main activity is: Management consultancy activities. Its registered office is in Zaventem. It employs on average 47,1 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0667.829.063
Incorporation: 19/12/2016
Legal form: Public limited company
Registered office: Weiveldlaan 3 box 5
1930 Zaventem · FlandreSee on map
Contributed capital: 118 600,00 €
Latest accounts: 30/09/2024
Average workforce: 47,1 ETP

Activities (NACE)

70200Management consultancy activities· main 70220Business and other management consultancy activities 63920Other information service activities 63990Other information service activities n.e.c.

Joint committees (3)

100
200
2000

Signals

Solid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debtsHigh revenue

Financials

Source · NBB, 8 filings

Trend over 8 financial years

	2024		2023		2022		2021		2020
Income statement
Revenue	8,4 M €	+19.7%	7 M €	+21.9%	5,7 M €	+23.7%	4,6 M €	+7.2%	4,3 M €
EBITDA	513,3 k €	-31.1%	744,7 k €	-12.5%	850,6 k €	+45.3%	585,2 k €	-0.6%	588,7 k €
Operating result	111,3 k €	-86.6%	832,2 k €	+9.9%	757,1 k €	+44.4%	524,3 k €	+7.9%	485,7 k €
Net result	-102,3 k €	-118%	577,7 k €	+3.3%	559,4 k €	+33.3%	419,8 k €	+43.9%	291,8 k €
Balance sheet
Equity	2,4 M €	-4.2%	2,5 M €	+84.3%	1,3 M €	+44.2%	926,3 k €	+52.7%	606,4 k €
Total assets	5 M €	-15.3%	5,9 M €	+58.1%	3,7 M €	+41.3%	2,6 M €	+12.1%	2,3 M €
Cash	1,1 M €	-44.5%	1,9 M €	+381%	399,9 k €	+130%	173,6 k €	+63.0%	106,5 k €
Debts	1,8 M €	-29.7%	2,6 M €	+18.0%	2,2 M €	+50.7%	1,5 M €	-0.5%	1,5 M €
Other
Workforce	47,1 ETP	-5.8%	50,0 ETP	+75.4%	28,5 ETP	+11.3%	25,6 ETP	+3.2%	24,8 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 2,5 M€ and 5 M€

See the valuation

Board of directors

Source · NBB, accounts to 30/09/2024

3 active · 21 ended

Active mandates

Anne Peeters

Director · since 01 novembre 2024 · until 01 novembre 2030

Active

Christopher Gauglitz

Director · since 01 novembre 2024 · until 01 novembre 2030

Active

Pharmalex France SAS

Director · since 01 novembre 2024 · until 01 novembre 2030

Represented by Åsa Pihlblad

Active

Ended mandates

Christopher Gauglitz

Director · since 30 juin 2023 · until 08 février 2028

Ended

Laurent Couston

Director · since 30 juin 2023 · until 08 février 2028

Ended

FRANCOIS DE WITTE

Director · since 24 janvier 2023 · until 24 janvier 2029

Ended

François De Witte

Director · since 24 janvier 2023 · until 08 février 2028

Ended

Full financial information

Source · NBB

	2024	2023	2022	2021	2020	2019
Type of account	Full model	Full model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/10/2023	01/01/2023	01/01/2022	01/01/2021	01/01/2020	01/01/2019
Closing of the financial year	30/09/2024	30/09/2023	31/12/2022	31/12/2021	31/12/2020	31/12/2019
Length of the financial year	12 months	9 months	12 months	12 months	12 months	12 months
Filing date	19/08/2026	23/07/2024	24/07/2023	29/07/2022	23/07/2021	23/07/2020
General meeting	03/07/2026	05/07/2024	06/06/2023	07/06/2022	01/06/2021	02/06/2020
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for 7 days

Annual accounts filings

Source · NBB, 8 filings

Model	Closing	General meeting	Filed	Language	Document
Full model	30/09/2024	03/07/2026	19/08/2026	Dutch	PDF
Full model	30/09/2023	05/07/2024	23/07/2024	French	PDF
Abridged model	31/12/2022	06/06/2023	24/07/2023	French	PDF
Abridged model	31/12/2021	07/06/2022	29/07/2022	French	PDF
Abridged model	31/12/2020	01/06/2021	23/07/2021	French	PDF
Abridged model	31/12/2019	02/06/2020	23/07/2020	French	PDF
Abridged model	31/12/2018	04/06/2019	07/06/2019	French	PDF
Abridged model	31/12/2017	12/06/2018	06/07/2018	French	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 2,5 M€ and 5 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 30/09/2024

3 active · 21 ended

Active mandates

Anne Peeters

Director · since 01 novembre 2024 · until 01 novembre 2030

Active

Christopher Gauglitz

Director · since 01 novembre 2024 · until 01 novembre 2030

Active

Pharmalex France SAS

Director · since 01 novembre 2024 · until 01 novembre 2030

Represented by Åsa Pihlblad

Active

Ended mandates

Christopher Gauglitz

Director · since 30 juin 2023 · until 08 février 2028

Ended

Laurent Couston

Director · since 30 juin 2023 · until 08 février 2028

Ended

FRANCOIS DE WITTE

Director · since 24 janvier 2023 · until 24 janvier 2029

Ended

François De Witte

Director · since 24 janvier 2023 · until 08 février 2028

Ended

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette publications

Source · Belgian Official Gazette

Registered office21/04/2026
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - BENAMING - MAATSCHAPPELIJKE ZETEL
PDF
Mandates21/04/2026
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - DENOMINATION - SIEGE SOCIAL
PDF
Mandates24/02/2026
DEMISSIONS, NOMINATIONS
PDF
Mandates20/01/2026
DEMISSIONS, NOMINATIONS
PDF
Mandates07/01/2025
DEMISSIONS, NOMINATIONS
PDF
Mandates26/04/2024
DEMISSIONS, NOMINATIONS
PDF
Capital / shares16/10/2023
CAPITAL, ACTIONS
PDF
Other03/08/2023
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - ASSEMBLEE GENERALE - ANNEE COMPTABLE
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

2024
Annual accounts 2024-102,3 k €↓
2023
Annual accounts 2023577,7 k €↑
2022
Annual accounts 2022559,4 k €↑
2021
Annual accounts 2021419,8 k €↑
2020
Annual accounts 2020291,8 k €↑
2019
Annual accounts 2019245,9 k €↓
2018
Annual accounts 2018247,9 k €↑
2017
Annual accounts 2017-29,2 k €
19/12/2016
IncorporationPublic limited company

PharmaLex Belgium

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline